Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Eddingpharm Gains China Rights To Omega-3 Product in $169 Million Deal

publication date: Feb 26, 2015
Eddingpharm, a China in-licensing company, signed a deal worth up to $169 million for China rights to Vascepa®, a prescription omega-3 drug from Amarin Corp., an Irish-US pharma. Vascepa lowers triglyceride levels. The deal includes a $15 million upfront payment. The remaining $154 million consists of development, regulatory and sales-based milestones. In addition, Eddingpharm will pay tiered double-digit royalties, which are capped in the high teens. Vascepa was granted US approval in 2012. More details....

Stock Symbols: (NSDQ: AMRN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital